Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...
Dr. Reddy’s Laboratories RDY is a major player in the generic drugs markets. The company reports its financial performance under three operating segments — Global Generics, Pharmaceutical Services & ...
Dr. Reddy's Laboratories Limited RDY reported fourth-quarter fiscal 2025 earnings of 22 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 20 cents per share. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results